The clinical features of acute ulcerative colitis in relapse closely resemble those of infectious colitis. Moreover, the disease remains localized to the mucosa of the colon, which is intimately associated with the faecal stream and its abundant microbial flora. Not surprisingly, therefore, much effort has gone into identifying microbial agents that might be an aetiological factor. To review an infective theory in the Diamond Jubilee year of the British Society of Gastroenterology is fitting, since one of the Society's founders, Sir Arthur Hurst, suggested in 1921 that ulcerative colitis might be caused by an infection closely related to Shigella dysenteriae, then known as Bacillus dysenteriae.
ESCHERICHIA COLI AND ULCERATIVE COLITIS Before the magnitude of the anaerobic faecal flora was recognized, the predominant faecal organism was thought to be Escherichia coli. Although almost universally present as a commensal in the bowel, E. coli is now seen to be a minority constituent of the flora as a whole, and five distinct groups can cause diarrhoea: * Enterotoxigenic * Enteropathogenic * Enteroinvasive * Enterohaemorrhagic * Enteroadherent Quantitative studies of the faecal flora in ulcerative colitis have produced confficting results. The proportion of coliforms to total viable bacteria in the stool of patients with ulcerative colitis was found by Seneca and Hendersonl to be more than 50-fold that of normal. However, others have seen no such quantitative differences in the flora24. Studies of the mucosal associated flora or rectal biopsies in patients with active ulcerative colitis showed fewer E. coli than in controls and the numbers increased with clinical improve-ment5.
The validity of this approach is open to question since diarrhoea from any cause may alter the relative proportions of organisms in the faeces, and the presence of inflamed, friable and bloody tissue may affect the recovery of viable Cumberland Infirmary, Newtown Road, Carlisle CA2 7HY, UK organisms. A more relevant approach is to examine qualitative differences in isolates from patients and controls. Interest in E. coli and ulcerative colitis followed the studies of Cooke2,67, who found an increased frequency of faecal E. coli with 'pathogenic' 0 serotypes in ulcerative colitis. The E. coli from patients with ulcerative colitis differed from control strains in being more likely to produce haemolysin and necrotoxin and to cause distension of rabbit ileal loops. Haemolysin producing strains were isolated more frequently in patients in relapse than from those in remission. Subsequent studies, however, suggested that these strains followed rather preceded relapse of colitis8.
The intimate mucosal association of bacteria and cell surfaces appears to be a prerequisite for colonization and the initiation of disease for a wide range of intestinal pathogens including E. coli. Dickinson et al.9 were the first to report an increased prevalence of faecal coliforms with in vitro adhesive properties in patients with ulcerative colitis. They examined the ability of E. coli to adhere to HeLa cells in tissue culture and found 35% of patients with active ulcerative colitis to be colonized by an adhesive E. coli, compared with only 5% of controls.
It would be premature to ascribe a primary pathogenic role on the basis of in vitro qualitative differences alone. The presence of adhesive E. coli in the faeces of patients with ulcerative colitis could be an incidental finding. The inflammatory process within the colon may expose receptors that would otherwise be masked. This 'unmasking' effect has been demonstrated in the urinary tract where treatment of the bladder mucosa with neuraminidase increased the adhesion of E. coli. A similar effect could operate in the colon of colitics secondary to the action of host or bacterial enzymes. Pinder et al.10 found adhesive strains in patients presenting in their first attack and suggested, therefore, that acquisition was not secondary to chronic gut inflammation.
The recognized adhesins of pathogenic E. coli demonstrate somatotropic localization via specific cell surface receptors on the target organ. The Hela cells used by Dickinson may not have been the ideal model; they are a neoplastic cell line derived from the genital tract, and enzymatic stripping methods used in the manipulation of the cells may result in the expression of receptors irrelevant to potential intestinal adherence. Pathogenic E. coli strains that cause diarrhoea demonstrate adhesion that is resistant to the C4) _i 612 sugar mannose. Type 1 pilus adhesion which is inhibited by mannose is expressed by many E. coli and does not seem to be associated with intestinal pathogenicity in man.
To address these issues, other workers have continued Dickinson's experiments using different cell substrates. With a buccal epithelial cell assay, patients with ulcerative colitis were shown to harbour E. coli that express mannoseresistant adhesion more commonly than controls11 13. This method has several advantages. It is quantitative and, since buccal epithelial cells can be obtained from patients, it allows assessment of host factors that may influence adhesion. Buccal epithelial cells express receptors similar to those of the intestine. Pathogenic E. coli can be cultured from the oropharynx of children with E. coli diarrhoea, and adhesive E. coli adhere both to buccal cells and to fetal enterocytes.
When buccal epithelial cells from differing sources were studied, the E. coli isolates from colitic patients had no greater affinity for cells derived from their host than for cells from other colitic patients or controlsl 1. Furthermore, adhesive strains were found in colitics in remission and in patients with Crohn's disease (Figure 1 ). In a group of patients with infective diarrhoea due to organisms recognized as causing colonic inflammation, the median adhesion index was only 14% compared with 43% for E. coli from patients with a relapse of ulcerative colitis. Only 100 -
-
27% of E. coli isolates from the infective group were adhesion positive (as defined by an adhesion index > 25%) compared with 86% in the inflammatory bowel disease group. These findings indicate that inflammation per se, in the short term, does not lead to acquisition of adhesive E. coil14. Previous treatment (including sulphasalazine, which has a sulphonamide component) does not appear to select for adhesive E. coli. 'Sticky' strains are found in those patients having their first attack, including those who have received no treatment, and their presence is unaffected by a history of exposure to sulphasalazine or sulphonamide resistance in the faecal E. coli isolates15.
When the rectal mucosal associated flora was studied5, there was no significant difference between the different patient groups in the distribution of E. coli showing mannose-resistant adhesion to Hep-2 cells. If bacterial adhesion is relevant to pathogenesis, one might expect adhesive E. coli to be represented more frequently in ulcerative colitis mucosa. This implies that the organism does not adhere to the cell surface in vivo. It was, however, noticed that Enterobacteriaceae, usually E. coli, were isolated less frequently and in lower numbers from patients with active colitis than controls. The rectal biopsy samples had been processed to remove mucus, and I have already referred to concerns about the recovery of viable bacteria from inflamed bloody tissue. Mucus may indeed play an important part in trapping bacteria. There the mucin produced by colitics differs qualitatively from normal mucus, and abnormal mucin might express receptors not usuallv exposed, leading to the selective colonization by E. coli with adhesive properties. A subepithelial connective tissue protein binding property in colitic faecal E. coli has been demonstrated by the agglutination of latex particles coated with fibronectin, collagen type II, or fibrinogen. The authors of this study suggested that this property could confer a selective advantage on E. coli, enabling the bacteria to dwell in 1 6 colonic lesions and hence retard the healing process .
What of attempts to demonstrate adhesion of colitic E. coli to rectal or colonic mucosal? Despite the use of various staining techniques including autoradiography and immu-nostaining17'18, these have met with no success with intact mucosa. Adhesion of organisms was sometimes seen in association with cut or disrupted surfaces, but this finding suggests that their role, if any, is as secondary invaders of diseased tissue. In theory, the profuse mucin production by mucosal explants could impair contact with the mucosal surface. Efforts to overcome this by increasing the bacterial load or inhibiting mucin production vvith N acetylcysteine impaired the viability of the mucosal sample17'19.
Routine histological examination of the colonic mucosa in patients with ulcerative colitis does not normally demonstrate mucosal associated bacteria. This, however, does not exclude their presence in vivo. Indeed they are not normally looked for and there is the problem of seeing only 'what we know'. Even those organisms known to be pathogenic and to adhere to or invade the intestinal mucosa (e.g. Campylobacter and Shigella species or enteropathogenic E. coli) are seldom seen with standard histological techniques. Alternative methods of fixation, sectioning or staining may be necessary. For example, Campylobacter species may require immunostaining to be identified adequately in tissue sections. Attempts to show colitic E. coli adhering in vivo have not been convincing despite use of a range of staining techniques including specific immunostaining against adhesive strains isolated from the faeces17. Again bacteria were seen on occasion in association with damaged areas or within the surface mucus. An electronmicroscopic study of colitic mucosa showed, in a proportion of cases, rod-like structures of a similar size to E. coli in close association with the mucosa17. Ohkusa et a].20, using an acridine-orange stain, showed rods (and cocci) invading the mucosa. In these studies, however, the organisms were not positively identified as E. coli.
Haemagglutination studies of colitic E. coli have not identified any of the recognized mannose-resistant adhesins (i.e. CFA 1/ 1); however, 42% of isolates expressed at least one mannose-resistant haemagglutinin 7.
The ability to resist the lethal effect of human serum colitic colon, particularly when blood and serum exude from the mucosal surface of the bowel during relapse. We know that there are no quantitative deficiencies of the complement system involved in bacterial killing in colitis. The functional bactericidal competence of serum from patients with ulcerative colitis is intact and the proportion of faecal E. coli showing serum resistance is not higher than normal2 1.
In the search for pathogenic hacteria in ulcerative colitis some workers have detected an in vitro cytopathic effect in faeces or E. coli isolates from patients. The numbers have, however, been small and the toxins were not identified 13 further
There have been reports of cases with presumed or known ulcerative colitis where verocytotoxin producing E. coli (VTEC) have been isolated16'22'23. In studies looking at larger numbers of colitics VTEC were not identified13 and antibodies to verocytoxin are not present in their sera (Burke D, et ai., unpublished).
In the HeLa cell studies reported by Dickinson, the invasive E. coli strains were not of a recognized enteroinvasive serotype. When the standard Sereny test for enteroinvasion was used no invasive strains were identified in patients with ulcerative colitis and no diseaserelated plasmid was identified17.
Serotyping alone is insufficient to indicate pathogenicity. The genetic determinants controlling the virulence of an organism are not always chromosomally mediated or restricted to one serotype and may be transmissible (via plasmids or bacteriophages). Plasmids are small extrachromosomal pieces of double-stranded DNA that are not normally essential to the cell's survival. They may carry information that controls not only their own replication but also many of the bacterium's 'acquired' properties notably, virulence factors such as toxin production, adhesion and enteroinvasion. Because such acquired properties are transferable between bacteria of different species, the qualitative differences seen in colitic E. coli might in theory represent acquisition by the patient's resident E. coli of 'virulence' markers from a previous, but transient, infective agent. This phenomenon could explain the reports of ulcerative colitis developing after a recognized gastrointestinal infection without persistence of the organism.
IMMUNE RESPONSE AND ESCHERICHIA COLI
Patients with ulcerative colitis possess agglutinating antibodies in their sera to a greater number of E. coli 0 antigens and in higher titres than controls24. In patients with ulcerative colitis, antibodies to a lipopolysaccharide extract of E. coli 014 cross-reacted with an antigen present in the might confer a survival advantage to bacteria inhabiting the 2S goblet cells of the colonic epithelium The Kunin antigen, which is common to the Enterobacteriaceae, is present in high concentration in E. coli 014 and antibodies to this antigen cross react with a goblet cell antigen, but attempts to demonstrate antibodies to goblet cells at the tissue level in vivo have been unsuccessful26.
The relevance of these antibodies to pathogenesis is unclear; they are not cytotoxic to colon cells (even in the presence of complement) and no correlation has been found between the presence of antibody and clinical severity, extent, or duration of disease. Cellular cytotoxicity to colonic epithelial cells can be detected in patients with ulcerative colitis and this effect can be blocked by incubating the patient's lymphocytes with a lipopolysaccharide extract of E. coli 019. Conversely, cytotoxicity for colonic epithelium can be induced in normal lymphocytes by incubation with this antigen27.
ANIMAL STUDIES
To gain some understanding of the mechanisms involved in ulcerative colitis, many researchers have turned to animal models. This approach has limitations, in particular the questionable validity of extrapolating the findings to human beings. Many models show similarities to the human disease, though the pathology often differs in localization and lack of chronicity. One interpretation is that the inflammatory changes seen in ulcerative colitis present a final common pathway in response to various stimuli.
The cotton-top tamarin (Sanguinus oedipus oedipus) can develop a chronic colitis closely resembling that of humans; it responds to sulphasalazine and there is a high incidence of colonic carcinoma. Mucin abnormalities similar to those in human ulcerative colitis are seen but, as in man, the aetiology remains obscure. There are difficulties with this model not least that these animals are an endangered species.
Guinea pigs that are fed degraded carrageenan, a substance derived from the red seaweed Eucheuma spinosum, acquire lesions morphologically comparable to those seen in ulcerative colitis. This colitis can not be induced in germfree animals28, but the relevant component of the faecal flora is uncertain. Pretreatment with metronidazole, active against anaerobic bacteria, prevents development of colitis but this agent has no effect on established disease. Pretreatment wvith gentamicin, sulphamethoxazole, or trimethoprim all active against aerobes does not prevent the development of ulceration but fewer and less severe lesions were seen in guinea pigs rendered Enterobacteriaceae-free by administration of sulphamethoxazole/trimethoprim29. Carrageenan-induced colitis can also be prevented by pretreatment with steroids and azathiopr-ine30. These findings suggest that some component of the the development of colitis in these models. Metronidazole has immunosuppressive properties and these rather than its antibiotic properties might partly explain its efficacy in preventing colitis.
The possibility that the immune system is involved in the development of ulcerative colitis provided a stimulus for further experimental investigation. Animals sensitized systemically to ovalbumin or bacterial lvsates develop haemorrhagic lesions after injection of the same antigen into intestinal tissue, resulting in a local Arthus or Schwartzman type reaction. Utilizing the Auer reaction, whereby an area of inflammation can localize a systemic antigen-antibody response, Kraft et a]. first sensitized rabbits to ovalbumin and a mild inflammation was then induced in the rectum with dilute formalin3l. This inflammation was transient unless the rabbits were rechallenged with ovalbumin, following which a more severe colitis-like lesion developed. Although morphologically similar to ulcerative colitis, it was not self-sustaining, resolving rapidly if the local irritant and antigen were not constantly applied. A chronic colitis in rabbits not dependent on the re-exposure to antigen or irritant was achieved by a modification of the Auer procedure whereby the animal was first immunized against an E. coli antigen32. A chronic colitis in rats was induced by injection of live or dead E. coli incorporated in Freund's adjuvant33. Interestingly, not all strains of E. coli were effective in inducing a colitis; thus, specific antigens are necessary to induce the disease. Cooke34 was unable to produce colitis in any rabbit by immunizing with E. coli antigens alone.
These phenomena may not be limited to E. coli. Enhancement of experimental colitis has also been achieved by immunization with Bacteroides vulgatus before carrageenan treatment; florid colitis develops when the animal is subsequently fed the organism. This effect is transferable to non-immune animals by transplantation of splenic tissue, an indication that cell-mediated mechanisms are involved35.
More recently, rodents with genetically engineered cytokine deficiencies have provided models of spontaneous and chronic intestinal inflammation. While these latter models support a role for an immunological abnormality in ulcerative colitis, again luminal bacteria seem to be a prerequisite to its development; inflammatory response was prevented or muted in animals reared in a germ-free environment36.
The fulfilment of Koch's postulates requires transmission of the disease to a suitable animal, but inoculation studies of faecal filtrates into monkeys, suckling mice, and rabbits have all been negative. The only positive results reported were the development of a granulomatous response after the inoculation of ulcerative colitis tissue into rabbits37. But other workers failed to confirm this finding or found a similar response with control tissue38. faecal flora and an intact immune system are necessary for IJOURNAL OF THE ROYAL SOCIETY OF MEDICINE Volume 90 November 1997
ERADICATION THERAPY
If a microbial agent is involved in the pathogenesis of ulcerative colitis, whether primary or secondary, antimicrobial therapy should be of benefit. In 1942 antitoxic Bacillus coli (E. coli) serum was reported beneficial in ulcerative colitis39. This finding might seem to support a role for E. coli in ulcerative colitis, but the study was uncontrolled and the observations could represent a nonspecific response (antidysenteric serum, Bargen-Logan serum, a vaccine against Bargen's streptococcus, and typhoid vaccine have all been reported to achieve the same therapeutic result).
What of antimicrobial treatments? In controlled trials metronidazole, active against anaerobes, was not found to be beneficial in ulcerative colitis40'41 nor was any overall benefit apparent with vancomycin, active against many Gram positive organisms. There appeared to be a reduction in the operation rate in those patients who had received vancomycin, and this advantage was not attributable to its activity against Clostridium difficile, since this organism was never found42.
If one contemplates antimicrobial therapy in colonic disease one needs to think of the concentration of the drug that can be achieved in the colon (which may be suboptimal for agents readily absorbed from the bowel) and the activity of the drug under anaerobic conditions. In an uncontrolled study the poorly absorbed sulphonamide succinyl sulphathiazole was reported beneficial in the management of ulcerative colitis43. It seemed most effective when administered topically by enema to patients with distal disease. The only controlled studies of sulphonamides in ulcerative colitis are those of sulphasalazine. The active component of this agent, however, is the aminosalicyclic acid moiety, the sulphonamide component merely acting as a carrier to the colon. In ulcerative colitis this agent has little lasting effect on the bacterial flora44 '45 Complete and permanent eradication of resident gut organisms is almost impossible to achieve with safety. The benefit of temporary eradication of E. coli was studied in a double-blind controlled trial of oral tobramycin, a poorly absorbed aminoglycoside, as an adjunct to standard therapy. All the original strains of E. coli were eradicated from 82% of the tobramycin treated group compared with a change in strain in only 9% of the placebo group. At endpoint, 74% of those treated with tobramycin were in clinical remission compared with only 43% of controls17 46 . When intravenous tobramycin was studied17 as an adjunct to corticosteroids no benefit was seen, but of course it would have had no effect within the lumen of the bowel or on the colonic flora. The efficacy of tobramycin seems to be shortlived; there was no benefit to maintenance of remission after treatment47.
Cooke7 studied the effect of altering the E. coli population in patients with ulcerative colitis by feeding them selected 'benign' strains in an attempt to replace the patients' resident E. coil. She was successful in implanting a 'non-pathogenic' strain into the colon of all of the patients studied. 10 of 14 patients treated this way were said to have benefited. Some patients in this uncontrolled study had been pretreated with neomycin to help establish the new strain and others were receiving corticosteroids. Nevertheless, if changing the strains of E. coli present in the faeces of patients with ulcerative colitis is feasible and of benefit48, the likely explanation is that a 'pathogenic' strain has been displaced.
In an anecdotal report, a patient with chronic ulcerative colitis unresponsive to standard medical treatment improved after implantation of a 'normal' faecal flora by faecal enemas49. This approach is helpful in patients with relapsing Clostridium dfficile associated diarrhoea, but we do not know which components in the faeces are important to 'normalize' the faecal ecology. CONCLUSION Qualitative differences between the faecal E. coli in patients with ulcerative colitis and controls have been identified. While these differences may be secondary to the disease process, it remains possible that these organisms play a primary aetiological role. This latter view needs serious consideration particularly since the properties identified include some that are recognized in pathogenic bacteria. Koch's postulates have not been fulfilled for these organisms in colitis. However, the notion of 'infection' and the part played by bacteria in gastrointestinal disease continue to evolve. One needs only to look at the radical change in our understanding and treatment of peptic ulcer disease that came from work on Helicobacter pylori. Here we have a relapsing remitting disorder where there is an immune response to an organism without its elimination and where eradication therapy is beneficial-characteristics with some analogies to ulcerative colitis.
